MR-guided Radiotherapy Boost: IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
Study summary
This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.
Eligibility
Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Histologically-proven localized prostate cancer.
* Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
* Low-risk: cT1-T2a, PSA \<10, and Gleason score 6
* Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
* High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7
* Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume
* Planned for EBRT (+/- ADT)
* ECOG 0 or 1
* 18 years of age or older
* Ability to provide written informed consent to participate in the study
Exclusion Criteria:
* Prior radiotherapy to pelvis
* Radiological evidence of regional or distant metastases at the discretion of the treating physician.
* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
* Ataxia Telangectasia and SLE
* Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
* Severe claustrophobia
Primary outcome measure(s)
Feasibility of MR-guided Linear Acceleratorfor tumour-targeted intra-prostatic dose escalation as boost — Baseline Total proportion of patients achieving predefined dosimetric parameters: PTV V100, PTV D90, Urethra V105, Rectum V75, Bladder V75
Trial sites (1)
Facility
City
Region
Status
University Health Network, Princess Margaret Hospital
Toronto
Ontario
More University Health Network, Toronto trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.